Univer le capital risque en région

Actualités

Symetis and Boston Scientific reach USD 435 million purchase agreement

Mars 2017

Symetis and Boston Scientific reach USD 435 million purchase agreement

Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease. Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions. Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.

Ecublens, Switzerland, 30 March 2017 - Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.
The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

 

Lire la suite du communiqué

Vous recherchez

Des fonds propres à partir de 30 000 €.
Un interlocuteur disponible et proche
de vos préoccupations.
Un allié vis-à-vis de
votre environnement.

Nos membres
Adhérer à l'UNICER

Nos partenaires

bpiFrance AFIC

CapinTech France Angels

voir tous nos partenaires

Contacter UNICER

Nous écrire 03 20 31 59 54

Contact
-